Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,620 | 266 | 2,317 |
| Samples | 685 | 111 | 561 |
| Peptides | 566 | 84 | 490 |
Function
PTPRO · Protein tyrosine phosphatase receptor type O
This gene encodes a member of the R3 subtype family of receptor-type protein tyrosine phosphatases. These proteins are localized to the apical surface of polarized cells and may have tissue-specific functions through activation of Src family kinases. This gene contains two distinct promoters, and alternatively spliced transcript variants encoding multiple isoforms have been observed. The encoded proteins may have multiple isoform-specific and tissue-specific functions, including the regulation of osteoclast production and activity, inhibition of cell proliferation and facilitation of apoptosis. This gene is a candidate tumor suppressor, and decreased expression of this gene has been observed in several types of cancer. [provided by RefSeq, May 2011].
Isoforms & Proteins
8 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 545 amino-acid changes on canonical ENST00000281171 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTPRO · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTPRO – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Melanoma | 18/210 9% | 102/1899 5% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 29/612 5% |
| Unknown | 0/10 0% | 2/29 7% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 34/810 4% |
| Other Solid Cancers | 1/94 1% | 59/1515 4% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 32/1390 2% |
| Gastric Carcinoma | 4/74 5% | 34/1809 2% |
| Colorectal Carcinoma | 14/143 10% | 51/3239 2% |
| Other Sarcomas | 2/69 3% | 12/699 2% |
| Neuroendocrine Tumour | 8/154 5% | 4/577 1% |
| Head and Neck Carcinoma | 3/85 4% | 21/1574 1% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 35/2550 1% |
| Mesothelioma | 1/62 2% | 2/165 1% |
| Hepatocellular Carcinoma | 3/46 7% | 25/2210 1% |
| Bladder Carcinoma | 0/58 0% | 12/956 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Biliary Tract Carcinoma | 1/54 2% | 10/950 1% |
| Cervical Carcinoma | 1/35 3% | 4/422 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Glioma | 0/52 0% | 15/2127 1% |
Mutation Distribution
Where PTPRO is mutated · all tissues, split by cell line vs tissue
How many mutations in PTPRO were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,620 mutations in PTPRO
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|